Adlai Nortye Doses First Patient in Global Phase 1 Trial for Pan-RAS Inhibitor AN9025

summarizeSummary

Adlai Nortye announced the dosing of the first U.S. patient in its global Phase 1 clinical trial for AN9025, an oral pan-RAS (ON) inhibitor targeting solid tumors with RAS mutations.

check_boxKey Events

• First Patient Dosed in Phase 1 Trial

  Adlai Nortye announced the dosing of the first U.S. patient in its global Phase 1 clinical trial for AN9025, an oral pan-RAS (ON) inhibitor.

• Advancing Pan-RAS Inhibitor AN9025

  AN9025 is an in-house discovered pan-RAS (ON) inhibitor with best-in-class potential, targeting a broad spectrum of RAS mutations in advanced solid tumors.

• Collaboration for Multi-Regional Trial

  The Phase 1 study is a multi-regional clinical trial conducted in collaboration with Jiangsu Aosaikang Pharmaceutical Co. Ltd., with Adlai Nortye retaining ex-China rights.

auto_awesomeAnalysis

This milestone marks significant progress in Adlai Nortye's clinical pipeline, particularly for AN9025, which is positioned as a potential best-in-class pan-RAS inhibitor. The initiation of this Phase 1 trial, following a recent substantial capital raise, demonstrates the company's commitment to advancing its innovative cancer therapies and provides a positive operational update for investors. Successful progression through early-stage trials is crucial for clinical-stage biotechnology companies.